表紙
市場調查報告書

全球核醫學診斷市場 (SPECT、PET) :分析與預測 (2015年∼2020年)

Nuclear Medicine Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 353811
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
全球核醫學診斷市場 (SPECT、PET) :分析與預測 (2015年∼2020年) Nuclear Medicine Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球核醫學診斷市場,預計至2019年達到176億美元,2014年∼2019年以 (CAGR) 12.29%的年複合成長率成長。

本報告提供全球核醫學診斷市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

目錄

  • 簡介
  • 調查手法
  • 摘要整理
  • 主要的推論
  • 市場概要與產業趨勢
  • 目前市場方案
  • 應用
  • 技術概要
  • 新的發展
  • 產業價值鏈分析
  • 波特的五力分析
  • 推動因素、阻礙因素、機會、課題分析
  • 推動市場要素
  • 阻礙市場要素
  • 市場課題
  • 市場區隔
  • 各類型產品
  • SPECT
  • PET
  • 其他
  • 市場區隔 (各地區) :各地區的佔有率與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 中東、北非
  • 南美
  • 競爭情形
  • M&A分析
  • 新產品的銷售
  • 契約、聯盟、夥伴關係
  • 主要供應商分析
  • Mallinckrodt
  • Lantheus Medical Imaging
  • IBA Group
  • Triad Isotope
  • Siemens Healthcare
  • NTP Radioisotopes
  • Bracco Pharma
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Nordion, Inc.
  • 太陽日酸
  • FUJIFILM Holdings
  • Eczacibasi-Monrol
  • Isotec, Inc.
  • Petnet Solutions, Inc.
  • 投資機會預測
  • 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53628

Nuclear medicine has a huge potential in treating cancer and cardiac diseases. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths, due to the growth and aging of the population, apart from other factors, such as smoking, poor diet, physical inactivity, and fewer childbirths. Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Nuclear medicine plays an important role in the diagnosis and management of patients with chronic diseases, which is a key growth factor for the market studied.

Key Market Trends

Technetium-99m Segment is Expected to Show Better Growth in the Forecast Years

Based on Type, it is segmented into SPECT and PET. The SPECT is further sub-segmented into Technetium-99m, Thallium-201, Iodine-123, Gallium-67, and Others. Technetium 99m is considered as the most widely used single isotope in several diagnostic procedures. Globally, approximately 30 million procedures are carried out every year, with technetium 99m (TC-99m), and this is expected to grow rapidly in the coming years. It is used in SPECT imaging, cardiac ventriculography, brain imaging, bone scans, and 3D scanning techniques. The growth and widespread applications of diagnostic nuclear medicine have been mainly driven by the easy availability of TC-99m. Furthermore, the increasing burden of non-communicable and chronic diseases, such as cancer and cardiac disorders, and the advancement in imaging technologies, such as SPECT/CT are fueling the demand for Technetium-99m in various applications.

North America Dominates the Nuclear Medicine Diagnostics Market

North America region is among the major contributor in this market due to the advancements in technology, and introduction of new radiopharmaceuticals for diagnosis. According to the National Oncology PET Registry, about 84% of more than 1,600 PET facilities in the United States have PET/CT systems. Thus, the emergence of molecular imaging, with new radiopharmaceuticals and new technologies, is likely to result in continued growth in the coming decades. Moreover, rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the nuclear medicine diagnostics market are - Bayer AG, Bracco SpA, Cardinal Health Inc., Curium SAS, GE Healthcare, Lantheus Holdings, Inc., NTP Radioisotopes SOC Ltd, and Sotera Health (Nordion, inc.).

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Cancer and Cardiac Disorders
    • 4.2.2 Increasing SPECT and PET Applications
    • 4.2.3 Widening Applications of Nuclear Medicine
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement and Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 SPECT
      • 5.1.1.1 Technetium-99m (TC-99m)
      • 5.1.1.2 Thallium-201 (TL-201)
      • 5.1.1.3 Iodine-123 (I-123)
      • 5.1.1.4 Gallium-67 (Ga-67)
      • 5.1.1.5 Others
    • 5.1.2 PET
      • 5.1.2.1 Fluorine-18
      • 5.1.2.2 Rubidium-82 (RB-82)
      • 5.1.2.3 Others
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Neurology
    • 5.2.4 Thyroid
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Bracco SpA
    • 6.1.3 Cardinal Health Inc.
    • 6.1.4 Curium SAS
    • 6.1.5 GE Healthcare
    • 6.1.6 Lantheus Holdings, Inc.
    • 6.1.7 NTP Radioisotopes SOC Ltd
    • 6.1.8 Sotera Health (Nordion, inc.)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS